Skip to content

The Big Business of Diabetes Drugs

June 13, 2013

There’s been a small run of Diabetes-related items in the New York Times recently and not-so-recently.  The one that caught my eye is the one in the New York Times by Jerry Avorn about clinical guidelines and how they can be influenced  That one made me think about some of the new diabetes drugs that have been getting press.  Glaxo-Smith Kline, which makes Avandia, was very happy the other day when the FDA said it will re-open the question about whether it’s drug is responsible for increased risk of heart attack  I also noticed that a new injectable one-a-week drug called Bydureon from Amylin just got approved even though there are concerns about thyroid cancer, pancreatitis, and cardiovascular problems  Victoza, by Novo Nordisk, is a similar drug.  That got me thinking: “are the new drugs better?  Which led me to Walecia Konrad’s article in 2011 about how the older drugs are better, safer, and cheaper

Hmmm… Why all these recent new treatments for diabetes?  Boys and girls, big big money.  We spent 22 Billion dollars on diabetes drugs last year.  Merck made 5.7 billion on the sale of Januvia and Janumet, it’s newest agents. Bydureon is estimated by the company to cost $4200 per person per year and make the company 1 billion dollars.  By contrast Metformin and Glipizide, which have been around for a long time, will run you about $120/year.  Avandia will run you $1,500/year.

Let’s look at effectiveness.  Maybe the cost is justified by the awesomeness of the newer drugs.  Your blood sugar is determined by four factors: the amount of insulin you make (insulin lowers blood sugar), how sensitive your insulin receptors are, how much glucagon you have (glucagon increases insulin production) and how much sugar your liver makes and your digestive system absorbs.  You can see that there are many points at which you can interfere with blood sugar levels with various drugs.    Metformin doesn’t increase insulin production.  It works by decreasing the amount of sugar your liver makes, making your insulin receptors more sensitive, and decreases intestinal absorption of sugars.  Avandia increases insulin sensitivity, and also doesn’t increase insulin production.  Bydureon is what we call a GLP-1 receptor agonist.  This means that it mimics the effects of the naturally-occurring hormone glucagon.  Glucagon increases insulin production.  So if your sugar is too high Bydureon will get you to release more insulin.  Glyburide does essentially the same thing, but Glyburide also decreases the amount of sugar the liver produces and increases the sensitivity of the insulin receptors.  Comparative effectiveness data tends to be surprisingly hard to find.  Metformin and Avandia are roughly equally effective.   Bydureon interacts at fewer regulation points than Glybyride, and comparison studies haven’t really been done.

OK, so the newer drugs are not more awesome.  Are they safer?  The Mayo Clinic does a really great job with this question on their website  All have side effects.  The older ones have sort of test-of-time safety profiles.  The newer ones, as I’ve said above, have some problems that may or may not be significant.  Why have companies spent so much money coming up with new versions of the same thing?  It’s all about the money.

So, take home message: start with the cheap, move to the expensive.  Unless you’re talking about shoes or husbands, you don’t get what you pay for.  What bothers me about the new diabetes drugs is not their mechanisms or side effects or even cost.  It’s that pharmaceutical companies are investing millions of dollars to come up with new drugs that do the same thing as old drugs, in order to get in on the market. AND that they spend millions more defending their products and promoting their products disingenuously.  I would love to see those companies invest their R&D money on things that are really new and really helpful, regardless of market value.  I would love to see them use all that lovely money to make more than shareholder returns.


From → Healthcare

  1. kris permalink

    The main problem with that argument is that it may not be true, Older drugs are like pushing a car in reverse by hiring a few extra tired workers, the older drugs are not safer then the newer drugs, in particular drugs like glipizide, glimepride, and glyburide, have been linked to early death and heart risks and beta cell dysfunction.

    The older drugs like glipizide are effective, but only for a short time, and it will make a problem worse, those drugs work day and night on your pancreas and eventually your beta cells die.

    The end result, the cheaper drugs are effective and then not only stop working but leave your body in a WORSE position then they were before.

    It’s like pushing a car up the hill in reverse with tired guys, sure you keep having them push but when they collapse the car rolls back to the ground and the guys are no longer in a position to push the car and even if they could they cycle will repeat itself till you have say one or two guys left.

    • Thanks for reading! I agree the safety profile for all the drugs, old and new, are not great. I argue that the side-effects of the older drugs are at least the devil you know as they say. I have not heard that glipizide really stops working as you say, but it is true that often another drug has to be added, one with a different mechanism of action. All in all, I propose that you start cheap and simple and go newer and more expensive if the older drugs don’t work.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

The Ideal Violinist

By Bayla Keyes

Eclectic Voices

Fiction, Monologues, Plays & More

Competing Diagnoses

How Americans talk about health care reform

Navigating Healthcare - Patient Safety and Personal Healthcare Management

A Guide to navigating Healthcare for parents, children and spouses who are concerned with managing their health and the health of their family

Children's Book Reviews


Dr. Vineet Arora's thoughts on medical training, patient care, healthcare policy, with tips for trainees

Wright on Health

Making complex issues in health policy and health services research accessible to all...

Dr John M

cardiac electrophysiologist, cyclist, learner

Navigating the healthcare system


Navigating the healthcare system

Whole Mama

Navigating the healthcare system

medicine for real

Navigating the healthcare system

%d bloggers like this: